Icon
+91 94997 68112
Login Register

TALZENNA - (0.25MG, 1MG, 0.5MG, 0.75MG, 0.1MG, 0.35MG)

TALAZOPARIB TOSYLATE None
0.25MG, 1MG, 0.5MG, 0.75MG, 0.1MG, 0.35MG
Less Than $1000 mn
None None
None None
None None
TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA
Yes
TALZENNA Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
*** *********

TALZENNA - (0.1MG, 0.25MG, 0.35MG, 0.5MG, 0.75MG, 1MG)

TALAZOPARIB TOSYLATE None
0.1MG, 0.25MG, 0.35MG, 0.5MG, 0.75MG, 1MG
Less Than $1000 mn
None None
None None
None None
TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. In combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Yes
TALZENNA Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.